Firma Immunic, Autor bei PR-Web

Immunic, Inc. Announces First Patients Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of IMU-838 in Combination with Oseltamivir for the Treatment of Patients with Moderate-to-Severe COVID-19

Posted on 27. July 202013. December 2023 by Firma Immunic Posted in General Tagged cancer, dosing, fiscal, immunic, immunic's, imu, market, nhs, patients, revenue, securities, statements, syndrome, ulcerative, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced enrollment of the first patients in an investigator-sponsored phase 2 clinical trial of the company’s selective […]

Immunic, Inc. to Join Russell 3000® Index

Posted on 22. June 202013. December 2023 by Firma Immunic Posted in Research / Development Tagged colitis, cov, covid, fiscal, immunic, immunic's, imu, index, market, revenue, securities, statements, syndrome, ulcerative, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that the company is set to join the broad-market Russell 3000® Index at the conclusion of the […]

Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19

Posted on 15. June 202013. December 2023 by Firma Immunic Posted in Research / Development Tagged calvid, colitis, dosing, fiscal, immunic, immunic's, imu, market, patients, revenue, securities, statements, syndrome, ulcerative, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced dosing of the first patients in its phase 2, CALVID-1 clinical trial of IMU-838, the […]

Immunic, Inc. Announces Proposed Public Offering of Common Stock

Posted on 10. June 202013. December 2023 by Firma Immunic Posted in General Tagged clinical, covid, fiscal, immunic, immunic's, imu, market, prospectus, revenue, roth, securities, statements, syndrome, treatment, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced it has commenced a public offering of shares of its common stock. Immunic intends to use […]

Immunic, Inc. Announces U.S. Food and Drug Administration Allowance of its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19

Posted on 9. June 202013. December 2023 by Firma Immunic Posted in Research / Development Tagged calvid, cells, colitis, fiscal, immunic, immunic's, imu, market, patients, revenue, securities, statements, syndrome, ulcerative, with

Immunic, Inc. (Nasdaq: IMUX),a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced receipt of regulatory allowance from the U.S. Food and Drug Administration (FDA) to initiate its phase […]

Immunic, Inc. to Host Virtual R&D Day Today, May 19, 2020

Posted on 19. May 202013. December 2023 by Firma Immunic Posted in General Tagged dosing, fever, fiscal, hcmv, hella, immunic, immunic's, imu, market, patients, revenue, securities, statements, syndrome, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, announced that it will host a virtual R&D Day today, May 19, 2020, from 9:00 am to 1:00 […]

Immunic, Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients

Posted on 14. May 202013. December 2023 by Firma Immunic Posted in General Tagged cell, colitis, dosing, fiscal, immunic, immunic's, imu, market, patients, revenue, securities, statements, syndrome, ulcerative, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that it has received first regulatory approval from Germany’s BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) to […]

Immunic, Inc. Announces Pricing of $15 Million Financing

Posted on 23. April 202013. December 2023 by Firma Immunic Posted in Research / Development Tagged altium, clinical, fiscal, immunic, immunic's, imu, market, prospectus, revenue, roth, securities, statements, syndrome, treatment, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that it has entered into securities purchase agreements with certain institutional investors, led by Altium Capital, […]

Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients

Posted on 22. April 202013. December 2023 by Firma Immunic Posted in General Tagged dosing, est, hcmv, hella, immunic, immunic's, imu, market, patients, revenue, statements, syndrome, ulcerative, vaccines, with

. – In Cellular Assays with SARS-CoV-2 Clinical Isolates, IMU-838 Shows Ability to Inhibit Viral Replication of SARS-CoV-2 – Live Webcast will be Held at 8:00am EST / 5:00am PST / 2:00pm CEST on Wednesday, April 22, 2020 Immunic, Inc. […]

Immunic, Inc. Reports Year End 2019 Financial Results and Highlights Recent Achievements

Posted on 17. March 202013. December 2023 by Firma Immunic Posted in Research / Development Tagged 4sc, caldose, dosing, fiscal, immunic, immunic's, imu, market, patients, psc, psoriasis, revenue, statements, ulcerative, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced financial results for the year ended December 31, 2019 and highlighted recent achievements. "In addition to […]